Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1.

• Published in: bioRxiv
• Main Authors: Choudhary, Alok, Calianese, David, Honnen, William, Kolloli, Afsal, Dikdan, Ryan J., Jaijyan, Dabbu, Song, Ge, Capozzola, Tazio, Sy, Chandler, Akkaraju, Vikash, Mattappallil, Arun, Rosania, Anthony, Khan, Salman, Lerman, Mark, Nikaein, Afzal, Subbian, Selvakumar, Chou, Ting-Chao, Andrabi, Raiees, Burton, Dennis, Pinter, Abraham
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Laboratory 04.05.2023
• Edition: 1.1
• Subjects: Immunology; COVID-19; Anti-RBD; Spike; SARS-CoV2; broadly neutralizing antibody; Hypermutated Ab; Cross-CoV2 neutralization; Omicron subvariants; Anti-RBM; Synergism

Choudhary et al. have isolated and characterized Acovimab, a broadly neutralizing RBM-specific human monoclonal antibody with a relatively high level of somatic hypermutation, which potently neutralizes SARS-CoV2 variants ranging from WuhanB.1 to OmicronBQ.1.1, but not the XBB.1.5 variant. Acovimab...